Investment analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.
Bio-Path Stock Performance
BPTH stock opened at $1.15 on Friday. Bio-Path has a fifty-two week low of $0.59 and a fifty-two week high of $12.00. The business has a 50 day moving average price of $0.90 and a 200 day moving average price of $1.22.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors and hedge funds own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- Upcoming IPO Stock Lockup Period, Explained
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- What is a Stock Market Index and How Do You Use Them?
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- P/E Ratio Calculation: How to Assess Stocks
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
